MKMin Kong

Min Kong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Min Kong has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Haixin Dong

    Department of Medical Laboratory, Affiliated Hospital of Jining Medical University, Shandong, People’s Republic of China

    2 shared publications
  • Hong Chang

    Department of Medical Laboratory, Affiliated Hospital of Jining Medical University, Shandong, People’s Republic of China

    2 shared publications
  • Jinyan Yan

    Department of Medical Laboratory, Affiliated Hospital of Jining Medical University, Shandong, People’s Republic of China

    2 shared publications
  • Guohang Pang

    Department of Medical Laboratory, Affiliated Hospital of Jining Medical University, Shandong, People’s Republic of China

    1 shared publication
  • Haiyang Sang

    Department of Medical Laboratory, Affiliated Hospital of Jining Medical University, Shandong, People’s Republic of China

    1 shared publication
  • Liqing Jiang

    Medical Laboratory Science, Affiliated Hospital of Jining Medical University, Jining Medical University, Shandong Jining, China

    1 shared publication

Latest Publications

  • Open Access

    Diagnostic Utility of Bronchoalveolar Lavage Metagenomic Next-Generation Sequencing for Pulmonary Mucormycosis: A Single-Center Retrospective Cohort Study

    by Xiao Yao, Haiyang Sang, Shuguang Gao, Xiaohang Hu, Jinyan Yan, Ting Liu, Hong Chang, Guohang Pang, Haixin Dong, Xiujuan Meng, et al.

    Background: Although pulmonary mucormycosis is rare, it is highly invasive and carries a significant mortality rate. Due to its nonspecific clinical manifestations, it is often misdiagnosed as other invasive fungal diseases. Bronchoalveolar lavage fluid metagenomic next-generation sequencing is a rapid, precise, and comprehensive method for pathogen detection, showing great potential in the early diagnosis of pulmonary mucormycosis in a single-center retrospective series. It provides clinicians with faster and more accurate etiological information, thereby improving patient outcomes and reducing mortality rates. Methods: This study conducted a retrospective analysis of the clinical data from 14 patients diagnosed with pulmonary mucormycosis between 1/6/2021 and 30/6/2024. Peripheral blood samples were collected to perform a complete blood count, measure C-reactive protein levels, and conduct 1,3-β-D-glucan and Galactomannan tests. Lung tissue samples were sent to the pathology laboratory for histological examination. Bronchoalveolar lavage fluid was subjected to fungal culture and metagenomic next-generation sequencing. Additionally, a three-month follow-up on the patients’ survival status was carried out via telephone. Results: Males accounted for 57.14% of the cases. Diabetes mellitus was present in 12 patients (85.71%, 12/14), and fever was observed in 12 patients (85.71%, 12/14). The 14 patients were categorized as proven cases (4 cases), probable cases (4 cases), and possible cases (6 cases). Two patients (14.29%, 2/14) were diagnosed with disseminated mucormycosis. Chest Computed Tomography scans revealed cavities in half of the patients (50.00%, 7/14). Fungal hyphae were identified in all the histopathological examinations (100%, 4/4). Metagenomic next-generation sequencing detected Mucorales pathogens in all the (100%, 14/14) cases, which is higher positivity than the positive rates of the 1,3-β-D-glucan test (35.71%, 5/14), Galactomannan test (42.86%, 6/14) and fungal culture (7.14%, 1/14). The turnaround time for metagenomic next-generation sequencing reports is 1– 3 days, which is much shorter than the time required to obtain results from fungal culture (2– 5 days). Additionally, metagenomic next-generation sequencing identified bacterial and viral co-infections, with 11 patients diagnosed as having mixed infections. All patients were treated with antifungal agents targeting Aspergillus species, such as voriconazole, posaconazole, isavuconazole, or amphotericin B, resulting in 9 patients improving, 2 patients being transferred to higher-level hospitals, and 3 patients discontinuing treatment. The 90-day follow-up revealed a mortality rate of 28.57%. Conclusion: Metagenomic next-generation sequencing can serve as an important complement to traditional diagnostic methods, enabling rapid and accurate differentiation of Mucorales from other fungi. This allows patients to receive timely and targeted antifungal therapy, playing a critical role in early intervention and improving prognosis.


  • Open Access

    The diagnostic value of bronchoalveolar lavage fluid metagenomic next-generation sequencing in critically ill patients with respiratory tract infections

    by Xiaohang Hu, Liqing Jiang, Xiaowei Liu, Hong Chang, Haixin Dong, Jinyan Yan, Xiaoya Zhou, Min Kong

    Metagenomic next-generation sequencing (mNGS) is an unbiased and rapid method for detecting pathogens. This study enrolled 145 suspected severe pneumonia patients who were admitted to the Affiliated Hospital of Jining Medical University. This study primarily aimed to determine the diagnostic performance of mNGS and conventional microbiological tests (CMTs) using bronchoalveolar lavage fluid samples for detecting pathogens. Our findings indicated that mNGS performed significantly higher sensitivity (97.54% vs 28.68%, P < 0.001), coincidence (90.34% vs 35.17%, P < 0.001), and negative predictive value (80.00% vs 13.21%, P < 0.001) but performed lower specificity than CMTs (52.17% vs 87.5%, P < 0.001). Streptococcus pneumoniae as the most common bacterial pathogen had the largest proportion (22.90%, 30/131) in this study. In addition to bacteria, fungi, and virus, mNGS can detect a variety of atypical pathogens such as Mycobacterium tuberculosis and non-tuberculous . Mixed infections were common in patients with severe pneumonia, and bacterial-fungal-viral-atypical pathogens were the most complicated infection. After adjustments of antibiotics based on mNGS and CMTs, the clinical manifestation improved in 139 (95.86%, 139/145) patients. Our data demonstrated that mNGS had significant advantage in diagnosing respiratory tract infections, especially atypical pathogens and fungal infections. Pathogens were detected timely and comprehensively, contributing to the adjustments of antibiotic treatments timely and accurately, improving patient prognosis and decreasing mortality potentially. IMPORTANCE: Metagenomic next-generation sequencing using bronchoalveolar lavage fluid can provide more comprehensive and accurate pathogens for respiratory tract infections, especially when considering the previous usage of empirical antibiotics before admission or complicated clinical presentation. This technology is expected to play an important role in the precise application of antimicrobial drugs in the future.